Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Spac sparkle wins over health techs
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
Europe needs to be clearer about Covid-19 vaccines
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
A new market beckons for Alzheimer’s blood tests
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Obfuscation and evasion: Astra shows how not to disclose data
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
The Huntington’s pipeline takes a blow
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Merck & Co makes the accelerated approval pathway its own
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
